Details for Patent: 11,753,401
✉ Email this page to a colleague
Which drugs does patent 11,753,401 protect, and when does it expire?
Patent 11,753,401 protects XPOVIO and is included in one NDA.
This patent has twenty-nine patent family members in seventeen countries.
Drugs Protected by US Patent 11,753,401
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY | ⤷ Try a Trial | |||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES | ⤷ Try a Trial | |||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Try a Trial | |||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,753,401
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2015301484 | ⤷ Try a Trial | |||
Australia | 2020203246 | ⤷ Try a Trial | |||
Australia | 2021286266 | ⤷ Try a Trial | |||
Canada | 2957266 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |